Registered title, quoted from ClinicalTrials.gov
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07555470, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically confirmed Grade 1-3a follicular lymphoma (FL), CD20-positive, with no evidence of histologic transformation
Inclusion criterion 7
Histologically confirmed Grade 1-3a, CD20-positive, Stage III/IV FL with no prior systemic therapy.
Inclusion criterion 13
Histologically confirmed Grade 1-3a, CD20-positive, Stage III/IV FL with no evidence of histologic transformation.、
Inclusion criterion 19
Relapsed or refractory disease, having received at least 1 prior systemic therapy regimen containing an anti-CD20 antibody
Inclusion criterion 20
No prior treatment with a CD20/CD3 bispecific antibody or an EZH2 inhibitor
Inclusion criterion 21
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Inclusion criterion 2
Must have at least one measurable lesion (longest diameter >1.5 cm)
Inclusion criterion 16
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) infection (RNA PCR positive).
Exclusion criterion 4
Concurrent other malignancies or history of malignancies, or anti-cancer therapy (including major surgery) within the last 4 weeks.
Exclusion criterion 5
Female subjects of childbearing potential must have a negative serum pregnancy test and agree to use highly effective contraception; male subjects must agree to use effective contraception.
Inclusion criterion 4
Pregnant or lactating women.
Exclusion criterion 3
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07555470, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Adequate hematologic and organ function
- Female subjects of childbearing potential must have a negative serum pregnancy test and agree to use highly effective contraception; male subjects must agree to use effective contraception.
- Voluntary written informed consent
- Cohort 1- Previously Untreated High-Risk FL:
- Histologically confirmed Grade 1-3a follicular lymphoma (FL), CD20-positive, with no evidence of histologic transformation
- Ann Arbor Stage III/IV
- No prior systemic therapy for FL
- Meeting at least one of the GELF criteria for indicating treatment
- FLIPI-1 or FLIPI-2 score of 3 to 5 (High risk)
- Cohort 2- Previously Untreated Low-Tumor-Burden FL:
- Histologically confirmed Grade 1-3a, CD20-positive, Stage III/IV FL with no prior systemic therapy.
- Absence of B symptoms or severe pruritus
- Low tumor burden (LTB) not meeting GELF criteria for treatment
- Must have at least one measurable lesion (longest diameter >1.5 cm)
- Patients who are suffering from the disease or prefer active management over a watch-and-wait approach
- Cohort 3-Relapsed or Refractory FL:
- Histologically confirmed Grade 1-3a, CD20-positive, Stage III/IV FL with no evidence of histologic transformation.、
- Relapsed or refractory disease, having received at least 1 prior systemic therapy regimen containing an anti-CD20 antibody
- No prior treatment with a CD20/CD3 bispecific antibody or an EZH2 inhibitor
- Presence of at least one measurable or evaluable lesion at relapse
Exclusion Criteria:
- Central nervous system (CNS) lymphoma, primary mediastinal lymphoma, or evidence of histologic transformation.
- Uncontrolled cardiovascular, cerebrovascular, coagulopathy, connective tissue, or severe infectious diseases.
- Pregnant or lactating women.
- Known history of human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) infection (RNA PCR positive).
- Concurrent other malignancies or history of malignancies, or anti-cancer therapy (including major surgery) within the last 4 weeks.
- Allergic reaction to the study drugs.
- Concurrent use of strong CYP3A4 inhibitors or strong CYP3A4 inducers that cannot be avoided
- Other medical or psychiatric conditions or laboratory abnormalities that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results.
Quoted from ClinicalTrials.gov, NCT07555470, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07555470, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.